安怀略行贿罪和科开医药单位行贿罪的公开，与近两年贵州省 医药领域的反腐风暴有关。 作者：张铃 封图：图虫创意 12月10日晚间，贵州医药流通龙头企业信邦制药(002390.SZ)发布公告，其因涉嫌单位行贿，近 期或将被起诉。 2024年3月，原贵阳医学院附属医院（下称"贵医附院"）党委副书记、院长王小林涉嫌严重违纪 违法被查，后被查明其涉案金额高达1.6亿元，受贿数额特别巨大。王小林曾是科开医药的法定代 表人和董事长，而安怀略则是王小林昔年的下属。 经济观察报注意到，2025年1月，贵州省纪委监委在反腐专题片中详细披露了王小林贪腐细节， 其中涉及安怀略和科开医药。 2001年至2014年，王小林任贵阳医学院党委委员、副院长，贵医附院党委副书记、院长。2002 年，王小林将贵阳医学院科技开发公司药品销售部改制为科开医药。 改制后，王小林任法定代表人兼董事长，并安排当时在贵医附院担任急门诊主任的安怀略任总经 理。此后，在王小林大力支持下，科开医药成为贵医附院最大的药品供应平台。 此次信邦制药被起诉，或源于其控股子公司科开医药。2025年2月26日，科开医药单位行贿罪及 实控人安怀略行贿罪一案被贵州省开阳县人民法院 ...

12月10日晚间，贵州医药流通龙头企业信邦制药（002390）(002390.SZ)发布公告，其因涉嫌单位行 贿，近期或将被起诉。 2024年3月，原贵阳医学院附属医院（下称"贵医附院"）党委副书记、院长王小林涉嫌严重违纪违法被 查，后被查明其涉案金额高达1.6亿元，受贿数额特别巨大。王小林曾是科开医药的法定代表人和董事 长，而安怀略则是王小林昔年的下属。 经济观察报注意到，2025年1月，贵州省纪委监委在反腐专题片中详细披露了王小林贪腐细节，其中涉 及安怀略和科开医药。 2001年至2014年，王小林任贵阳医学院党委委员、副院长，贵医附院党委副书记、院长。2002年，王小 林将贵阳医学院科技开发公司药品销售部改制为科开医药。 改制后，王小林任法定代表人兼董事长，并安排当时在贵医附院担任急门诊主任的安怀略任总经理。此 后，在王小林大力支持下，科开医药成为贵医附院最大的药品供应平台。 2013年上半年，科开医药与某国企就资产并购事宜签订合作意向书。但是，这遭到了安怀略的反对。 "安怀略极力地反对和该国企合作，因为被该国企兼并了以后，他也就失去了总经理的权力。"在贵州省 纪委监委制作的反腐专题片中，王小林说。 此 ...

Core Viewpoint - The company, Xinbang Pharmaceutical, is facing legal scrutiny due to allegations of corporate bribery, which may impact its reputation and business development [1][2]. Group 1: Legal Issues - Xinbang Pharmaceutical received a notice from the prosecution regarding an alleged corporate bribery case, with materials forwarded from the supervisory committee [1]. - The company is currently awaiting further information from its legal counsel regarding the case, as the notice did not include specific details about the allegations [1][3]. - If found guilty of corporate bribery, the company could face fines ranging from 100,000 yuan to double the amount of the crime, and responsible individuals may face imprisonment and fines [2]. Group 2: Financial Impact - Following the announcement of the legal issues, Xinbang Pharmaceutical's stock price dropped by 9.88% to 3.74 yuan per share, with a total market capitalization of 72.7 billion yuan [1]. - The company reported a revenue of 22.78 billion yuan and a net profit of 945 million yuan from its subsidiary, Keke Pharmaceutical, which constitutes significant portions of Xinbang's overall financial performance [5]. - The company's third-quarter revenue for 2025 was 14.21 billion yuan, a decline of 6.42% year-on-year, with a net profit decrease of 26.87% [7]. Group 3: Historical Context - Keke Pharmaceutical, a key asset of Xinbang, has a history linked to corruption cases involving former executives, including the previous chairman, An Huailue [3][4]. - The acquisition of Keke Pharmaceutical in 2014 marked a significant shift in control and management within Xinbang, with An Huailue playing a crucial role in the process [4][5]. - The ongoing legal issues may be connected to previous corruption cases within the Guizhou medical system, indicating a broader context of corruption in the region [3].

| | | 2021 年 6 月，根据公司第七届董事会第二十四次会议的决议、2020 年 9 月 23 日召开的 2020 年第四次临时股东大会的决议和《贵州信邦 制药股份有限公司与贵州金域实业投资合伙企业（有限合伙）之附条件生效的非公开发行股票认购协议》，并经中国证券监督管理委员会证监 许可[2021]520 号文《关于核准贵州信邦制药股份有限公司非公开发行股票的批复》的核准，同意公司本次非公开发行不超过 36,000 万股新 股。 公司向贵州金域实业投资合伙企业（有限合伙）定向非公开发行 A 股股票 36,000 万股，每股发行价格为人民币4.20 元，募集资金总额为 人民币 151,200.00 万元。增发后总股本变更为 202,722.8611 万股。 (责任编辑：关婧) 中国经济网北京12月11日讯 信邦制药（002390.SZ）昨日晚间披露公告，公司于近日收到检察机关《审查起诉阶段委托辩护人/申请法律援 助告知书》、《犯罪嫌疑人诉讼权利义务告知书》，主要内容为：对公司涉嫌单位行贿一案，检察机关已经收到监察委员会移送起诉的材料。 根据《中华人民共和国刑事诉讼法》第三十四条、第三十五条、第二百七十八条 ...

Core Viewpoint - Guizhou Xibang Pharmaceutical Co., Ltd. is facing potential prosecution for alleged corporate bribery, which may adversely affect its brand reputation, business expansion, and future development [1] Group 1: Company Background - Founded in 1995, Guizhou Xibang Pharmaceutical was established by Zhang Guanfeng, who acquired a failing state-owned pharmaceutical factory [2] - The company went public in April 2010, becoming the first listed company in Qiannan Prefecture [2] - In 2013, Xibang Pharmaceutical acquired 98.25% of Keke Pharmaceutical, which was formed from the sales department of the affiliated hospital of Guizhou Medical University [2] Group 2: Ownership Changes - In 2017, Zhang Guanfeng sold 21.04% of his shares to Zhu Jiman, who was the actual controller of Yuheng Pharmaceutical [3] - Zhu Jiman's control was short-lived due to liquidity issues, leading to the judicial freezing of shares in 2018 [3] - By June 2021, An Huailue and An Ji, father and daughter, became the third actual controllers of Xibang Pharmaceutical, holding a combined 25.0468% of shares [3] Group 3: Business Operations - Xibang Pharmaceutical's business spans hospitals, pharmaceutical commerce, and manufacturing [3] - As of the first half of 2025, the company reported revenue of 284.5 million yuan, a decrease of 6.62% year-on-year, and a net profit of 10.7 million yuan, down 6.69% from the previous year [3] - The company operates six medical institutions and has a comprehensive sales network covering major hospitals in Guizhou [4] Group 4: Industry Context - The pharmaceutical industry in China is undergoing a crackdown on corruption, with several high-ranking officials in Guizhou facing legal issues [5][6] - The ongoing anti-corruption efforts may impact the operational environment for companies like Xibang Pharmaceutical [5]

昨日涨停的信邦制药(002390.SZ)今日跌停，报3.74元，总市值72.7亿元。消息上，信邦制药公告称，公司近日收到检察机关《审查起诉阶段委托辩护人/申请 法律援助告知书》、《犯罪嫌疑人诉讼权利义务告知书》，对公司涉嫌单位行贿一案，检察机关已收到监察委员会移送起诉的材料。该事项可能对公司品牌 声誉、业务拓展及未来发展产生不利影响。目前案件处于审查起诉阶段，最终结果以司法机关出具的法律文书为准。 ...

Group 1 - Dingyang Technology has launched the SPB3000X series source load simulator, which includes three models: SPB3100X, SPB3200X, and SPB3300X, featuring high precision, low ripple noise, and fast transient response [1] - Ningbo Huaxiang plans to acquire 40% of Fengmei Power's equity from SAIC Volkswagen, with the total acquisition involving 100% equity [2] - ST Jiaotou will implement a capital reserve conversion to increase share capital, with a total of 267 million shares to be converted [3] Group 2 - Century Huatong's subsidiary Guosheng Capital holds 19.5887 million shares of Moer Thread, accounting for 4.8968% of the total share capital before the IPO [4] - Meidike intends to introduce strategic investors to its subsidiary, with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [5] - Baiyun Airport reported a 12.58% year-on-year increase in passenger throughput in November, totaling 7.3228 million passengers [6] Group 3 - Shengda Resources' subsidiary Honglin Mining has received approval for a three-month extension for trial production [7] - ST Yigou's subsidiary Suning International is expected to increase net profit by approximately 992 million yuan from the sale of eight subsidiaries [8][9] - Huayi Brothers reported overdue debts totaling 52.5 million yuan, exceeding 10% of its audited net assets for 2024 [10] Group 4 - Wanshun New Materials plans to acquire 100% of Eurofoil Luxembourg for 12.3889 million euros, enhancing its aluminum foil production capabilities [11] - Wuhan Tianyuan's subsidiary plans to invest approximately 600 million yuan in two energy storage projects [12] - Maike Biological's subsidiary has received a product registration certificate for a new automatic cell morphology analyzer [13] Group 5 - CATL intends to register for the issuance of bonds not exceeding 10 billion yuan, primarily for project construction and working capital [14] - Yuntianhua plans to acquire 100% of Tianyao Chemical for 36.8858 million yuan, enhancing its fine phosphorus chemical product line [15] - Fucheng Technology's controlling shareholder has reduced its stake by 1.0429 million shares [16] Group 6 - Zhili Fang plans to reduce its stake by up to 1.2% of the company's total shares [17][18] - Qianzhao Optoelectronics' chairman intends to reduce his stake by up to 0.02% [19] - Sanmu Group's subsidiary plans to sell 75 office properties for 24.1068 million yuan [20] Group 7 - Zhuangyuan Pasture's director plans to reduce his stake by up to 3% of the company's total shares [21] - Chongqing Pharmaceutical's subsidiary has signed a licensing agreement with Pfizer, potentially earning up to 50 million USD in milestone payments [22] - Yongqing Environmental Protection's shareholder plans to reduce its stake by up to 1% [23] Group 8 - Lens Technology plans to acquire 100% of PMG International Co., Ltd., enhancing its capabilities in server cabinet business [24] - Xinbang Pharmaceutical is facing prosecution for alleged unit bribery, but its control remains unchanged [25] - Meian Health's shareholders plan to reduce their stake by up to 3% of the company's total shares [26] Group 9 - Central Plaza's subsidiary has decided to suspend operations due to ongoing operational difficulties [27] - Dawn Co. plans to acquire 80% of Ningbo Aisikai for 516 million yuan, including the transfer of related patents and technologies [28] - Kweichow Moutai will distribute over 30 billion yuan in cash dividends based on its 2025 mid-term profit distribution plan [29] Group 10 - Baiyun Airport has received approval from the CSRC for a stock issuance to specific targets [29] - Zai Sheng Technology reported that revenue from aerospace-related products will account for less than 0.5% of its total revenue in 2024 [30]

来源：格隆汇 英思特股东丁远达拟减持不超过1.9925%股份;裕兴股份股东北京人济拟减持不超过1%股份;庄园牧场董事马红富拟减持不超过3%股份;智立方 实际控制人的一致行动人拟减持不超过1.2%股份;徕木股份股东方培喜拟减持不超过145.24万股公司股份;天奈科技多名股东拟合计减持不超 2.5%股份;航天工程股东国创基金和新车基金合计减持729.05万股公司股份;汇通能源股东上海洪赢拟减持不超过0.44%股份;信邦制药涉嫌单位 行贿，检察机关已经收到监察委员会移送起诉的材料;永辉超市股价可能存在短期涨幅较大后的大幅下跌 | | | 12月11日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 | 主要内容 | | 股东减持 | 英思特 | 远达拟减持不超过1.9925%股份 | | | 裕兴股份 | 北京人济拟减持不超过1%股份 | | | 庄园牧场 | 董事马红富拟减持不超过3%股份 | | | 智立方 | 实际控制人的一致行动人拟减持不超过1.2%股份 | | | 徕木股份 | 股东方培喜拟减持不超过145.24万股公司股份 | | | 天奈科技 | 多名股东拟合计减持不超2 ...

Focus Events - The Federal Reserve announced a 25 basis point reduction in the federal funds rate target range to between 3.5% and 3.75%, marking the third consecutive rate cut this year and the sixth since the rate cut cycle began in September 2024 [1] Macro News - The Ministry of Agriculture and Rural Affairs is launching a consumption promotion activity titled "Special Products for the New Year" to boost agricultural product consumption during the upcoming holiday season [3] - The International Monetary Fund (IMF) has raised China's economic growth forecast for 2025 to 5%, an increase of 0.2 percentage points from its previous report [5] Industry Dynamics - The National Medical Products Administration is supporting companies in enhancing the research and development of innovative drugs and medical devices, with a focus on original products and breakthrough technologies [6] - China's AI industry has surpassed 900 billion yuan, with applications reaching 657, a year-on-year increase of 61.8% [9] Company Focus - Muxi Co., Ltd. reported that online investors abandoned the subscription of 20,349 shares, with a total subscription amount of 10.09 billion yuan [12] - Wuliangye and Kweichow Moutai announced significant mid-year cash dividends, with Wuliangye distributing 100.07 billion yuan and Kweichow Moutai distributing 300.01 billion yuan [14] - Century Huatong disclosed an indirect holding in Moer Thread, estimating a profit impact of approximately 640 million yuan for the fourth quarter of 2025 [16] - Huayi Brothers announced overdue debts totaling 52.5 million yuan, exceeding 10% of its audited net assets for 2024 [23] - CATL plans to register bonds not exceeding 10 billion yuan for project construction and working capital [24] - JD.com is acquiring a property in Hong Kong for approximately 3.473 billion HKD [25]

Group 1 - Xinfang Pharmaceutical is facing prosecution for alleged corporate bribery, which may negatively impact its brand reputation, business expansion, and future development [1] - The case is currently in the review and prosecution stage, with the final outcome dependent on legal documents issued by judicial authorities [1] Group 2 - Boji Pharmaceutical's actual controller Wang Tingchun and his concerted parties have collectively reduced their stake in the company by 2.98%, amounting to approximately 11.49 million shares [2] - The share reduction was executed through block trading and centralized bidding, and it is part of a compliant plan that does not alter the company's control [2] - This reduction is likely aimed at optimizing asset allocation, which may temporarily affect investor sentiment [2] Group 3 - Yifang Biotechnology has announced plans to issue H-shares and apply for a listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness [3] - The company is currently in discussions with relevant intermediaries regarding the details of the issuance and listing, which have not yet been finalized [3] - The A+H share strategy is expected to broaden international financing channels and support the development of innovative drugs in oncology and other fields [3]